Renal Cell Carcinoma: Balancing Efficacy Endpoints in First-Line Treatment

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians balance key efficacy endpoints when selecting first-line therapy for renal cell carcinoma. The panel explores the relative importance of objective response rate, durability of benefit, and overall survival in real-world clinical decision-making. Dr. Ramalingam and Dr. Ged highlight that while overall survival remains a gold standard endpoint, early and meaningful responses can be particularly important for patients with high disease burden or symptomatic disease. The discussion also addresses how durability of response contributes to long-term disease control and influences treatment sequencing. Panelists emphasize that these endpoints are not considered in isolation but are weighed alongside patient characteristics, risk profiles, and treatment tolerability. This segment underscores the complexity of translating clinical trial data into individualized treatment strategies in renal cell carcinoma.